雄激素剥夺疗法在前列腺癌患者中的应用与轻度认知障碍风险。
Androgen Deprivation Therapy Use and Risk of Mild Cognitive Impairment in Prostate Cancer Patients.
机构信息
School of Medicine, University of Puerto Rico, San Juan, Puerto Rico.
Mayo Clinic Alix School of Medicine and Center for Clinical and Translational Science.
出版信息
Alzheimer Dis Assoc Disord. 2021;35(1):44-47. doi: 10.1097/WAD.0000000000000415.
INTRODUCTION
We examined the association between androgen deprivation therapy (ADT) use and the risk of mild cognitive impairment (MCI) among prostate cancer patients.
METHODS
We included 241 cognitively unimpaired men, aged 70 to 90, with a history of prostate cancer before enrollment in the population-based Mayo Clinic Study of Aging. Using the Rochester Epidemiology Project medical records-linkage system, ADT use and length of exposure were abstracted. Follow-up visits occurred every 15 months and MCI diagnoses were made based on clinical consensus. Cox proportional hazards models, with age as the timescale, were used to examine the association between ADT use (yes/no) and length of exposure with the risk of MCI adjusting for education, apolipoprotein E, depression, and the Charlson Index score.
RESULTS
There was no association between any ADT use (27.8% of participants) and the risk of MCI in the multivariable model [hazard ratio (HR), 1.25; 95% confidence interval (CI), 0.75-2.10]. Although not significant, there was an ADT dose-response relationship for risk of MCI: <5 years versus no use (HR, 1.08; 95% CI, 0.60-1.96) and ≥5 years versus not use (HR, 1.89; 95% CI, 0.83-4.27).
CONCLUSION
ADT use among prostate cancer patients was not associated with an increased risk of developing MCI.
引言
我们研究了雄激素剥夺疗法（ADT）的使用与前列腺癌患者发生轻度认知障碍（MCI）的风险之间的关系。
方法
我们纳入了 241 名认知正常的男性，年龄在 70 至 90 岁之间，在进入基于人群的 Mayo 诊所老龄化研究之前有前列腺癌病史。使用罗切斯特流行病学项目医疗记录链接系统，提取 ADT 使用情况和暴露时间。每隔 15 个月进行一次随访，根据临床共识诊断 MCI。使用 Cox 比例风险模型，以年龄为时间尺度，调整教育、载脂蛋白 E、抑郁和 Charlson 指数评分后，检验 ADT 使用（是/否）和暴露时间与 MCI 风险之间的关系。
结果
在多变量模型中，任何 ADT 使用（27.8%的参与者）与 MCI 风险之间均无关联[风险比（HR），1.25；95%置信区间（CI），0.75-2.10]。尽管没有统计学意义，但 ADT 剂量与 MCI 风险之间存在相关性：<5 年与未使用（HR，1.08；95%CI，0.60-1.96）和≥5 年与未使用（HR，1.89；95%CI，0.83-4.27）。
结论
前列腺癌患者使用 ADT 与发生 MCI 的风险增加无关。
Zotero 插件